Exact Mass: 342.2670994
Exact Mass Matches: 342.2670994
Found 486 metabolites which its exact mass value is equals to given mass value 342.2670994,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Megestrol
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03A - Hormonal contraceptives for systemic use > G03AC - Progestogens G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DB - Pregnadien derivatives L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02A - Hormones and related agents > L02AB - Progestogens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents D000970 - Antineoplastic Agents
2alpha-Methyl-11-oxoprogesterone
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid is found in nuts. 2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid is a minor constituent of cashew nut shel D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
Guggulsterone
Guggulsterone is an ingredient in many nutritional supplements. Guggulsterone is a plant sterol derived from the gum resin (guggulu) of the tree Commiphora mukul. This sterol can inhibit NF-κB activation and downregulate the expression of inflammatory gene products such as COX-2 and MMP-9, which are major players in the development of arthritis. Guggulsterone also can suppress osteoclastogenesis induced by RANKL (receptor activator of NF-κB ligand), a bone-resorbing cytokine. The anti-inflammatory activity of C. mukul (guggul) has been compared with that of NSAIDs, namely phenylbutazone and ibuprofen. Guggulsterone is used to treat obesity, diabetes, hyperlipidemia, atherosclerosis, and osteoarthritis, and has been recently shown to antagonize the farnesoid X receptor and decrease the expression of bile acid-activated genes. It modulates activation of NF-kappaB, which has been closely linked with inflammatory diseases affected by guggulsterone. (PMID: 17475558, 15322087) [HMDB] Guggulsterone is an ingredient in many nutritional supplements. Guggulsterone is a plant sterol derived from the gum resin (guggulu) of the tree Commiphora mukul. This sterol can inhibit NF-κB activation and downregulate the expression of inflammatory gene products such as COX-2 and MMP-9, which are major players in the development of arthritis. Guggulsterone also can suppress osteoclastogenesis induced by RANKL (receptor activator of NF-κB ligand), a bone-resorbing cytokine. The anti-inflammatory activity of C. mukul (guggul) has been compared with that of NSAIDs, namely phenylbutazone and ibuprofen. Guggulsterone is used to treat obesity, diabetes, hyperlipidemia, atherosclerosis, and osteoarthritis, and has been recently shown to antagonize the farnesoid X receptor and decrease the expression of bile acid-activated genes. It modulates activation of NF-kappaB, which has been closely linked with inflammatory diseases affected by guggulsterone. (PMID: 17475558, 15322087).
13-Hydroxy-9-methoxy-10-oxo-11-octadecenoic acid
13-Hydroxy-9-methoxy-10-oxo-11-octadecenoic acid is found in cereals and cereal products. 13-Hydroxy-9-methoxy-10-oxo-11-octadecenoic acid is isolated from corn. Isolated from corn. 13-Hydroxy-9-methoxy-10-oxo-11-octadecenoic acid is found in cereals and cereal products.
MG(P-18:0/0:0/0:0)
1-(1Z-octadecenyl)-sn-glycerol is an ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
Propylene glycol stearate
Propylene glycol stearate is used as an emulsifier in food processing especially for margarine. Also as a defoamer and stabilise It is used as an emulsifier in food processing especies for margarineand is also as a defoamer and stabiliser.
17-Hydroxymethylethisterone
17-Hydroxymethylethisterone is a metabolite of danazol. Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. Also known as 17alpha-ethinyl testosterone. Before becoming available as a generic drug, Danazol was marketed as Danocrine in the United States. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis in the early 1970s. Although effective for endometriosis, its use is limited by its masculinizing side-effects. (Wikipedia)
14-oxo-DoHE(1-)
14-oxo-DoHE(1-) is also known as 14-oxo-(4Z,7Z,10Z,12E,16Z,19Z)-Docosahexaenoate. 14-oxo-DoHE(1-) is considered to be practically insoluble (in water) and acidic
N-Myristoyl Asparagine
C18H34N2O4 (342.25184440000004)
N-myristoyl asparagine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Asparagine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Asparagine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Asparagine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Pregn-4-en-20-yn-3-one, 17-hydroxy-2-(hydroxymethyl)-, (2alpha,17alpha)-
2-Hydroxy-6-pentadeca-8,11,14-trienyl benzoic acid
2-[4-(Carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid
Cardenolide
Medica 16
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120[1][2].
Retinyl propionate
4-(10,13-Dimethyl-2,3,4,5,6,7,8,9,11,12,14,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)oxolan-2-one
Trimegestone
MEDICA 16
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120[1][2].
24-Nor-cholen-(4)-dion-(3.22)|24-nor-cholene-(4)-dione-(3.22)|24-norchol-4-ene-3,22-dione
(E, E)-form/2, 5-Dihydroxy-3-(3, 7, 11-trimethyl-2, 6, 10-dodecatrienyl)benzaldehyde|3-farnesyl-2,5-dihydroxybenzaldehyde
20,21,22,23,24,25,26,27-octanorcucurbit-5-ene-3,7,16-trione|octanorcucurbitacin B
20,21,22,23,24,25,26,27-octanorcucurbit-5-ene-3,7,17-trione|octanorcucurbitacin A
10-acetoxy-9-hydroxyamphilecta-8,10,12,14-tetraene
2-hydroxyhenicosanoic acid
A 2-hydroxy fatty acid that is henicosanoic acid substituted by a hydroxy group at position 2.
Me ester-11,12,13-Trihydroxy-9,15-octadecadienoic acid
2-(7-hydroxy-4,8-dimethyl-3E,8-nonadienyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene A
5-methyl-2-[(2E,7Z)-3,7,11-trimethyl-2,7-dodecadien-9-onyl]benzo-1,4-quinone
2-[1,3,5,7-Tetramethyl-8-ethylbicyclo[4.2.0]octa-2,4-diene-7-yl]-3,5-dimethyl-6-methoxy-4H-pyran-4-one
5-methyl-2-[(2E,6E)-3,7,11-trimethyl-2,6-dodecadien-9-onyl]benzo-1,4-quinone
4-methoxy-2-methyl-6-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]phenol|farnesylol
Tricyclo[6.3.1.0(1,5)]dodecan-9-ol, 2-benzoyloxy-4,4,8-trimethyl-
methyl (9S,10R,11E,13S,15E)-9,10,13-trihydroxyoctadec-11,15-dienoate
(10R)-3c-Acetoxy-10r.13c-dimethyl-17c-vinyl-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren|3-O-acetylpregna-5,20-dien-3beta-ol|3beta-acetoxy-pregnadiene-(5,20)|3beta-acetoxypregna-5,20-diene|Essigsaeure-(pregnadien-(5.20)-yl-(3beta)-ester)|pregna-5,20-dien-3beta-ol-3-acetate|pregna-5,20-dien-3beta-yl acetate
3beta-Dimethylamino-23-nor-con-5-en|3beta-dimethylamino-23-nor-con-5-ene|conessimine
2-(3-hydroxy-8-methyl-4-methyliden-7-nonaenyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene B
7-oxo-20,21,22,23,24,25,26,27-octanor-14,18-cycloapotirucalla-1-en-3,4-olide|simaroubin E
2R-(9-hydroxy-4,8-dimethyl-3E,7E-nonadienyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene D
2(R),3(S),4(S)-3,18-methylene-2alpha-acetoxyspongia-13(16),14-diene
12-Acetoxy-abieta-8,11,13-trien-7-on|12-acetoxy-abieta-8,11,13-trien-7-one|sugiol acetate|Sugiol-Acetat|Sugiolacetat
Icosanedioic acid
An alpha,omega-dicarboxylic acid that is the 1,18-dicarboxy derivative of octadecane.
cyclohexamantane|[12.12.02,11.03,16.05,18.06,11.07,20.09,22.010,25.012,17.012,21.013,24]hexacosane|[12312]hexamantane
Me ester-(9S,10E,12S,13S,15Z)-9,12,13-Trihydroxy-10,15-octadecadienoic acid
3-geranyl-4-hydroxy-5-(3,3-dimethylallyl)-benzoicacid|3-geranyl-4-hydroxy-5-(3,3-dimethylallyl)-benzoic acid|3-geranyl-4-hydroxy-5-(3-methyl-2-butenyl)benzoic acid|3-geranyl-4-hydroxy-5-(3?,3?-dimethylallyl)benzoic acid|5-geranyl-4-hydroxy-5-(3-methyl-2-butenyl)-benzoic acid|myrsinoic acid|myrsinoic acid A
2-(8-hydroxy-4,8-dimethyl-3E,6Z-nonadienyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene C
5beta,19-epoxy-20,21,22,23,24,25,26,27-octanorcucurbit-6-ene-3,17-dione|octanorcucurbitacin C
(8Z,11Z,14Z)-5-(heptadeca-8,11,14-trienyl)benzene-1,3-diol|5,6-Dihydro-(all-Z)-5-(5,8,11,14-Heptadecatetraenyl)-1,3-benzenediol|5-heptadecatri-8(Z),11(Z),14(Z)-enylresorcinol
21-hydroxyhenicosanoic acid
An omega-hydroxy fatty acid that is henicosanoic acid in which one of the hydrogens of the terminal methyl group has been replaced by a hydroxy group.
C22H30O3_2-Hydroxy-6-[(8Z,11Z)-8,11,14-pentadecatrien-1-yl]benzoic acid
2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11,14-trienyl]benzoic acid
4Z,7Z,10Z,13Z,15E,19Z-17-keto-docosapentaenoic acid
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
5-((8Z,11Z,14Z)-heptadeca-8,11,14-trien-1-yl)resorcinol
5-((5Z,8Z,11Z)-heptadeca-5,8,11-trien-1-yl)resorcinol
5-((8Z,11Z,14E)-heptadeca-8,11,14-trienyl) resorcinol
4,7,10,13,16,19-Docosahexaenoic acid, methyl ester
(6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
Retinyl Propionate
D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids
2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo[3.3.3]undecane
C18H39N4P (342.29121840000005)
cocamidopropyl βine
C19H38N2O3 (342.28822779999996)
C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D013501 - Surface-Active Agents
1-Methyl-3-tetradecyl-1H-imidazolium nitrate
C18H36N3O3 (342.27565260000006)
9-Octadecenoic acid,12-hydroxy-, 2-hydroxyethyl ester, (9Z,12R)-
3-(2-hydroxypropoxycarbonyl)-2-prop-2-enyl-2,3-dipropylhexanoic acid
Trimegestone
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C389 - Oral Contraceptive
Cardenolide
D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides
Myrsinoic acid A
A monohydroxybenzoic acid that is 4-hydroxybenzoic acid substituted by a geranyl group at position 3 and a prenyl group at position 5. Isolated from Myrsine seguinii, it exhibits anti-inflammatory activity.
1,3-Benzenediol, 5-(8,11,14-heptadecatrienyl)-, (Z,Z,Z)-
L-Valine, N-(1-L-lysyl-L-prolyl)-
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D009074 - Melanocyte-Stimulating Hormones
(4Z,7Z,10Z,12E,14E)-15-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,12,14-pentaenoic acid
(13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid
An epoxy fatty acid consisting of (4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid having an epoxy group at the 13,14-position. An intermediate lipid in specialized proresolving mediators
2-hydroxyethyl (E)-12-hydroxyoctadec-9-enoate
[3-carboxy-2-[(E)-dodec-5-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[(1S)-3-carboxy-1-[(E)-dodec-2-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[(E)-2-(carboxymethyl)-2-hydroxy-3-oxotetradec-4-enyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[3-carboxy-2-[(E)-dodec-2-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
(3-Carboxy-2-dodec-11-enoyloxypropyl)-trimethylazanium
C19H36NO4+ (342.26441960000005)
[3-carboxy-2-[(E)-dodec-9-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[3-carboxy-2-[(E)-dodec-4-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[3-carboxy-2-[(E)-dodec-7-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[3-carboxy-2-[(E)-dodec-8-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[3-carboxy-2-[(E)-dodec-3-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[3-carboxy-2-[(E)-dodec-6-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
5-[2,4-dihydroxy-6-[(E)-3-hydroxyoct-1-enyl]cyclohexyl]pentanoic acid
(4Z,7Z,10Z,13Z,15E,19Z)-17-Oxodocosahexaenoic acid
An oxodocosahexaenoic acid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid in which the oxo group is located at position 17. An intermediate of specialised proresolving mediators.
(4Z,7Z,10Z,14E,16Z,19Z)-13-Oxodocosahexaenoic acid
An oxodocosahexaenoic acid that is (4Z,7Z,10Z,14E,16Z,19Z)-docosahexaenoic acid in which the oxo group is located at position 13. An intermediate of specialised proresolving mediators.
omega-(3-Oxo-17-beta-hydroxy-4-androsten-17-alpha-yl) propionic acid lactone
14-oxo-DoHE
An oxo fatty acid that consists of (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid carrying a single oxo substituent at position 14.
(1S,3S,4R,7S,8S,11S,12S,13S,15R,20R)-7-Formamido-20-isocyanoisocycloamphilectane
A tetracyclic diterpenoid that is hexadecahydropyrene substituted by isocyano group at position 8, methyl groups at positions 1, 4, 7 and 8 and a formamido group at position 1. Isolated from the tropical marine sponge Cymbastela hooperi, it exhibits antiplasmodial activity.
(4Z,7Z,10Z,13Z)-15-{(3R)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-ylidene}pentadeca-4,7,10,13-tetraenoic acid
L-Leucine, N-(N-acetyl-L-leucyl)-, butyl ester
C18H34N2O4 (342.25184440000004)
(20R)-20-hydroxyhenicosanoic acid
An (omega-1)-hydroxy fatty acid that is henicosanoic acid in which the 20-pro-R hydrogen is replaced by a hydroxy group.
6beta,17-Dihydroxy-3,5-cyclo-5alpha,17alpha-pregn-20-ene-21-carboxylic acid, gamma-lactone
(4Z,7Z,10Z,13Z)-15-{(3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-ylidene}pentadeca-4,7,10,13-tetraenoic acid
(17R)-17-ethynyl-17-hydroxy-2-(hydroxymethyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
(2R,8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-spiro[cyclopenta[a]phenanthrene-17,2-furan]-3,5(2H,4H)-dione
[3-carboxy-1-[(Z)-dodec-5-enoyl]oxypropyl]-trimethylazanium
C19H36NO4+ (342.26441960000005)
[(2~{S})-2,3-bis(oxidanyl)propyl] heptadec-9-enoate
[1-hydroxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] acetate
[1-hydroxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] butanoate
[1-hydroxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] propanoate
(4AS,5S,8AS)-(-)-5alpha-(3-Hydroxypropyl)-8A-methoxymethoxymethyl-5beta-methyl-3,4,4A,5,6,7,8,8A-octahydronaphthalen-1(2H)-one1-ethylene acetal
Octane-3,6-dimethyl-1,8-bis-(2-oxytetrahydro-2H-pyranyl)
(10,13-Dimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) propanoate
(1-acetyloxy-3-hydroxypropan-2-yl) (Z)-tetradec-9-enoate
(1-hydroxy-3-propanoyloxypropan-2-yl) (Z)-tridec-9-enoate
(4Z,8E,10Z,13Z,16Z,19Z)-7-oxodocosahexaenoic acid
A oxodocosahexaenoic acid that consists of (4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoic acid carrying an oxo substituent at position 7. An intermediate of specialised proresolving mediators.
(16S,17S)-epoxy-(4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoic acid
An epoxy fatty acid consisting of (4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoic acid having an epoxy group located at the 16,17-position. An intermediate lipid in specialized proresolving mediators.
DG(16:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
2-(8-hydroxy-4,8-dimethylnona-3,6-dien-1-yl)-2,7-dimethylchromen-5-ol
3-{[(1r,4ar,8ar)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-4-hydroxybenzoic acid
(3as,3br,9as,9bs,11as)-3a,6,6,9b,11a-pentamethyl-2h,3h,3bh,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-1,4,7-trione
(3z,7e,11e,13r)-13-methoxy-3,7,11-trimethylbicyclo[12.2.2]octadeca-1(16),3,7,11,14,17-hexaene-15,17-diol
methyl 3-methoxy-4,7-dimethyl-9-(2-methylprop-1-en-1-yl)-5,6,6a,7,8,9-hexahydro-4h-phenalene-1-carboxylate
3-hydroxy-3-isopropyl-6,8a-dimethyl-1,2,3a,4,5,8-hexahydroazulen-4-yl benzoate
4-hydroxy-3-[(2z,6z)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzoic acid
n,6,7,13-tetramethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-18-en-16-amine
13-methoxy-3,7,11-trimethylbicyclo[12.2.2]octadeca-1(16),3,7,11,14,17-hexaene-15,17-diol
5-[(8z,11z,14z)-heptadeca-8,11,14-trien-1-yl]benzene-1,3-diol
(3r,3as,4s,8ar)-3-hydroxy-3-isopropyl-6,8a-dimethyl-1,2,3a,4,5,8-hexahydroazulen-4-yl benzoate
(2e,4z,6z)-7-[2-(2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl)ethyl]-8h-oxocin-3-ol
3-[(3e,6e,8r)-11-(furan-3-yl)-8-methoxy-4,8-dimethylundeca-3,6-dien-1-yl]furan
4-methoxy-5-methyl-2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]phenol
methyl (4r,6as,7s,9s)-3-methoxy-4,7-dimethyl-9-(2-methylprop-1-en-1-yl)-5,6,6a,7,8,9-hexahydro-4h-phenalene-1-carboxylate
3-[11-(furan-3-yl)-8-methoxy-4,8-dimethylundeca-3,6-dien-1-yl]furan
2,5-dihydroxy-3-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzaldehyde
(1r,2r,4as,5s,8r,8ar)-1,5-diisocyano-2,5-dimethyl-8-(6-methylhept-5-en-2-yl)-octahydronaphthalen-2-ol
(2e)-3-[(1s,3r,4r,7r,8r,11s)-3-[(2z)-but-2-en-2-yl]-4,6,8,10,11-pentamethyl-2-oxatricyclo[5.3.1.0⁴,¹¹]undeca-5,9-dien-8-yl]prop-2-enoic acid
(1r,2r,5s,6r,9r,12r,13r,16s)-n,6,7,13-tetramethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-18-en-16-amine
4-hydroxy-3-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzoic acid
3-[(4e,6s,8e)-11-(furan-3-yl)-6-methoxy-4,8-dimethylundeca-4,8-dien-1-yl]furan
1-(2,5-dihydroxy-3-methylphenyl)-3,7,11-trimethyldodeca-2,6,10-trien-5-one
(1r,2s,5r,8s,9r)-9-hydroxy-4,4,8-trimethyltricyclo[6.3.1.0¹,⁵]dodecan-2-yl benzoate
10'(z),13'(e),15'(e)-heptadecatrienylhydro-173quinone
{"Ingredient_id": "HBIN000206","Ingredient_name": "10'(z),13'(e),15'(e)-heptadecatrienylhydro-173quinone","Alias": "NA","Ingredient_formula": "C23H34O2","Ingredient_Smile": "CC=CC=CCC=CCCCCCCCCCC1=C(C=CC(=C1)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9382","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
anacardicacid d
{"Ingredient_id": "HBIN015966","Ingredient_name": "anacardicacid d","Alias": "NA","Ingredient_formula": "C22H30O3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14276","TCMID_id": "1130","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(2r)-2-[(3r)-3-hydroxy-8-methyl-4-methylidenenon-7-en-1-yl]-2,7-dimethylchromen-5-ol
(1s)-3-[(3r,4r)-3-ethyl-1-methylpiperidin-4-yl]-1-(6-methoxyquinolin-4-yl)propan-1-ol
3-methoxy-5-methyl-2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]phenol
2-{[(2r,4s,4as,8as)-2,4,8,8a-tetramethyl-1,3,4,4a,5,6-hexahydronaphthalen-2-yl]methyl}-6-methoxycyclohexa-2,5-diene-1,4-dione
9-(5-hydroxy-2,7-dimethylchromen-2-yl)-2,6-dimethylnon-6-en-4-one
2-(3-hydroxy-8-methyl-4-methylidenenon-7-en-1-yl)-2,7-dimethylchromen-5-ol
1-(1-methoxyethylidene)-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-dione
4-hydroxy-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzoic acid
(2r)-2-[(3e,7e)-9-hydroxy-4,8-dimethylnona-3,7-dien-1-yl]-2,7-dimethylchromen-5-ol
(2r)-2-(4,8-dimethylnona-3,7-dien-1-yl)-6-methoxy-2,8-dimethyl-3,4-dihydro-1-benzopyran
2-(9-hydroxy-4,8-dimethylnona-3,7-dien-1-yl)-2,7-dimethylchromen-5-ol
(5s,9r,13r,16s)-n,n,6,13-tetramethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-18-en-16-amine
(3e,5s,10r)-3,17,17-trimethyl-7-methylidene-15-oxatricyclo[8.5.2.0¹³,¹⁶]heptadeca-1(16),3,13-trien-5-yl acetate
4-[(1e)-heptadeca-1,3,5-trien-1-yl]benzene-1,2-diol
1-hydroxy-3,6,9-trimethyl-4-(2-methylprop-1-en-1-yl)-5,6,6a,7,8,9-hexahydro-4h-phenalen-2-yl acetate
(2s)-3-[(9z)-octadec-9-en-1-yloxy]propane-1,2-diol
3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-4-hydroxy-6-methyl-5-(3-methylbut-2-en-1-yl)cyclohexa-3,5-diene-1,2-dione
(2r)-2-[(3e,6z)-8-hydroxy-4,8-dimethylnona-3,6-dien-1-yl]-2,7-dimethylchromen-5-ol
2-[(1r,6r,7s,8r)-8-ethyl-1,3,5,7-tetramethylbicyclo[4.2.0]octa-2,4-dien-7-yl]-6-methoxy-3,5-dimethylpyran-4-one
(1r)-3-[(3r,4r)-3-ethyl-1-methylpiperidin-4-yl]-1-(6-methoxyquinolin-4-yl)propan-1-ol
3-(3-ethyl-1-methylpiperidin-4-yl)-1-(6-methoxyquinolin-4-yl)propan-1-ol
(7-isopropyl-1,4a-dimethyl-9-oxo-3,4,10,10a-tetrahydro-2h-phenanthren-1-yl)methyl acetate
(15s)-15-propylbicyclo[14.2.2]icosa-1(18),16,19-trien-2-yne-17,20-diol
(3e,7z,11e,13r)-13-methoxy-3,7,11-trimethylbicyclo[12.2.2]octadeca-1(16),3,7,11,14,17-hexaene-15,17-diol
2-methyl-5-(3,7,11-trimethyl-9-oxododeca-2,6-dien-1-yl)cyclohexa-2,5-diene-1,4-dione
4-methoxy-5-methyl-2-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)phenol
(2s)-3-{[(1z)-16-methylheptadec-1-en-1-yl]oxy}propane-1,2-diol
2-methoxy-3,5-dimethyl-6-[1,3,5-trimethyl-6-(pent-2-en-2-yl)cyclohexa-2,4-dien-1-yl]pyran-4-one
2-{[(1e,2s,4as,8as)-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-ylidene]methyl}-6-methoxycyclohexa-2,5-diene-1,4-dione
(3e,7e,11z)-13-methoxy-3,7,11-trimethylbicyclo[12.2.2]octadeca-1(16),3,7,11,14,17-hexaene-15,17-diol
2-hydroxy-3,6,9-trimethyl-4-(2-methylprop-1-en-1-yl)-5,6,6a,7,8,9-hexahydro-4h-phenalen-1-yl acetate
2-methyl-5-(3,7,11-trimethyl-9-oxododeca-2,7-dien-1-yl)cyclohexa-2,5-diene-1,4-dione
(2r)-2-(8-hydroxy-4,8-dimethylnona-3,6-dien-1-yl)-2,7-dimethylchromen-5-ol
2-[(2,4,8,8a-tetramethyl-1,3,4,4a,5,6-hexahydronaphthalen-2-yl)methyl]-6-methoxycyclohexa-2,5-diene-1,4-dione
5,9,17,17-tetramethyl-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-ene-8,16-dione
n-methyl-n-[(9e)-16-(pyridin-3-yl)hexadec-9-en-11-yn-1-yl]hydroxylamine
2-methoxy-3,5-dimethyl-6-[(1r,6s)-1,3,5-trimethyl-6-[(2e)-pent-2-en-2-yl]cyclohexa-2,4-dien-1-yl]pyran-4-one
3-methoxy-5-methyl-2-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)phenol
5-[(9e,11z)-heptadeca-9,11,16-trien-1-yl]benzene-1,3-diol
3-(3,7-dimethylocta-2,6-dien-1-yl)-4-hydroxy-5-(3-methylbut-2-en-1-yl)benzoic acid
2-{[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-5-methoxycyclohexa-2,5-diene-1,4-dione
2-hydroxy-3-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzoic acid
(2r)-2-(hydroxymethyl)-1,4-dioxacycloicosane-5,20-dione
(2e,6e)-1-(2,5-dihydroxy-3-methylphenyl)-3,7,11-trimethyldodeca-2,6,10-trien-5-one
(z)-methoxy[16-(pyridin-3-yl)hexadec-7-yn-1-ylidene]amine
(2r)-2-[(3e,7r)-7-hydroxy-4,8-dimethylnona-3,8-dien-1-yl]-2,7-dimethylchromen-5-ol
(3as,3br,9as,9bs,11ar)-3a,6,6,9b,11a-pentamethyl-1h,3h,3bh,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-2,4,7-trione
(5as,7as,11as,11br)-5a,8,8,11a-tetramethyl-6,7,7a,9,10,11,11b,12-octahydro-5-oxatetraphene-1-carboxylic acid
(1r,4s,5s,9s,12s,13s)-5,9,17,17-tetramethyl-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-ene-8,16-dione
(2e,4z,6z)-7-{2-[(4as,8as)-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]ethyl}-8h-oxocin-3-ol
(6e,10e)-12-(2,6-dihydroxy-4-methylphenyl)-2,6,10-trimethyldodeca-2,6,10-trien-4-one
3,17,17-trimethyl-7-methylidene-15-oxatricyclo[8.5.2.0¹³,¹⁶]heptadeca-1(16),3,13-trien-5-yl acetate
12-(2,6-dihydroxy-4-methylphenyl)-2,6,10-trimethyldodeca-2,6,10-trien-4-one
(1r,2s,5s,6s,9r,12s,13r,16s)-n,6,7,13-tetramethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-18-en-16-amine
(2r)-2-(7-hydroxy-4,8-dimethylnona-3,8-dien-1-yl)-2,7-dimethylchromen-5-ol
9a,11a-dimethyl-1-(3-oxobutan-2-yl)-1h,2h,3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-one
4-hydroxy-3-[(6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzoic acid
3-[(1e)-heptadeca-1,3,5-trien-1-yl]benzene-1,2-diol
(2r)-2-[(3e)-4,8-dimethylnona-3,7-dien-1-yl]-6-methoxy-2,8-dimethyl-3,4-dihydro-1-benzopyran
7-[2-(2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl)ethyl]-8h-oxocin-3-ol
18-hydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-ene-6,15-dione
(15r)-15-isopropylbicyclo[14.2.2]icosa-1(18),16,19-trien-2-yne-17,20-diol
methyl 2-{3-[2-(3-ethylpiperidin-1-yl)ethyl]-1h-indol-2-yl}propanoate
3-[11-(furan-3-yl)-6-methoxy-4,8-dimethylundeca-4,8-dien-1-yl]furan
(2e)-1-(2,5-dihydroxy-3-methylphenyl)-3,7,11-trimethyldodeca-2,6,10-trien-5-one
2-(hydroxymethyl)-1,4-dioxacycloicosane-5,20-dione
2-{[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-6-methoxycyclohexa-2,5-diene-1,4-dione
n,n,6,13-tetramethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-18-en-16-amine
3-[(5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl)methyl]-4-hydroxybenzoic acid
4-methoxy-2-methyl-6-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)phenol
(6e)-9-(6-hydroxy-2,7-dimethylchromen-2-yl)-2,6-dimethylnon-6-en-4-one
3a,6,6,9b,11a-pentamethyl-2h,3h,3bh,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-1,4,7-trione
4-[(1s,3ar,3br,9as,9bs,11as)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]-5h-furan-2-one
(4bs,8as)-2-isopropyl-4b,8,8-trimethyl-10-oxo-6,7,8a,9-tetrahydro-5h-phenanthren-3-yl acetate
(2r)-2-[(3e)-7-hydroxy-4,8-dimethylnona-3,8-dien-1-yl]-2,7-dimethylchromen-5-ol
4-methoxy-2-methyl-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]phenol
(1e,3as,3br,9ar,9bs,11as)-1-(1-methoxyethylidene)-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,7-dione
(2e,6z)-1-(2,5-dihydroxy-3-methylphenyl)-3,7,11-trimethyldodeca-2,6,10-trien-5-one
(4s)-7-[(2r,5s)-5-decyloxolan-2-yl]heptane-1,4-diol
2,5-dihydroxy-3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzaldehyde
(3s,3ar,4r,8ar)-3-hydroxy-3-isopropyl-6,8a-dimethyl-1,2,3a,4,5,8-hexahydroazulen-4-yl benzoate
2-{8-ethyl-1,3,5,7-tetramethylbicyclo[4.2.0]octa-2,4-dien-7-yl}-6-methoxy-3,5-dimethylpyran-4-one
2,6,6,11-tetramethyl-7-oxapentacyclo[13.3.1.0¹,¹⁵.0²,¹².0⁵,¹¹]nonadec-9-ene-3,8-dione
(1r,2s,5s,6s,9r,12s,13r,16s)-n,n,6,13-tetramethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-18-en-16-amine
2-methoxy-3,5-dimethyl-6-[1,3,6-trimethyl-4-(pent-2-en-2-yl)bicyclo[3.1.0]hex-2-en-6-yl]pyran-4-one
[(1r,4as,10as)-7-isopropyl-1,4a-dimethyl-9-oxo-3,4,10,10a-tetrahydro-2h-phenanthren-1-yl]methyl acetate
2-(7-hydroxy-4,8-dimethylnona-3,8-dien-1-yl)-2,7-dimethylchromen-5-ol
(4s,6s,6ar,9s)-1-hydroxy-3,6,9-trimethyl-4-(2-methylprop-1-en-1-yl)-5,6,6a,7,8,9-hexahydro-4h-phenalen-2-yl acetate
(1r,2r,3r,5r,10r,11r,14s)-3-hydroxy-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadec-8-ene-7,15-dione
2-methyl-5-[(2e,7z)-3,7,11-trimethyl-9-oxododeca-2,7-dien-1-yl]cyclohexa-2,5-diene-1,4-dione
4a-hydroxy-2-methyl-3-(non-1-en-1-yl)-3h,9h,9ah,9bh-cyclopenta[f]chromen-5-one
2-methoxy-3,5-dimethyl-6-[(1s,4s,5r,6s)-1,3,6-trimethyl-4-[(2e)-pent-2-en-2-yl]bicyclo[3.1.0]hex-2-en-6-yl]pyran-4-one
(2r)-2-(3-hydroxy-8-methyl-4-methylidenenon-7-en-1-yl)-2,7-dimethylchromen-5-ol
2-methoxy-3,5-dimethyl-6-[(1s,6s)-1,3,5-trimethyl-6-[(2e)-pent-2-en-2-yl]cyclohexa-2,4-dien-1-yl]pyran-4-one
methyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate
(1r,3s,8r,11s,12s,16s,18r)-18-hydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-4-ene-6,15-dione
(2r)-2-{2-[(1r)-2,2-dimethyl-6-methylidenecyclohexyl]ethyl}-8-methoxy-2-methylchromen-6-ol
2-[(10z,13e,15e)-heptadeca-10,13,15-trien-1-yl]benzene-1,4-diol
methyl (2r)-2-(3-{2-[(3s)-3-ethylpiperidin-1-yl]ethyl}-1h-indol-2-yl)propanoate
[(1r,4as,10ar)-7-isopropyl-1,4a-dimethyl-9-oxo-3,4,10,10a-tetrahydro-2h-phenanthren-1-yl]methyl acetate
(2r)-3-(c-hydroxycarbonimidoyl)-2-[(1-hydroxytetradecylidene)amino]propanoic acid
C18H34N2O4 (342.25184440000004)